The market launch of the new drug requires successful clinical trials and regulatory approval such as FDA. The goal is to start Phase 1 trials in 2024, and enter Phase III trials in late 2025 to early 2026. If successful, this new drug could be a significant hope for diabetes patients, potentially reducing medical expenses and socio-economic burdens. It is also expected to be effective against diabetes complications.